Australia's most trusted source of pharma news
Sunday, 30 August 2015
Lost Your Access?
Hep C listings unlikely before 2016
If Australia listed all the new hep C meds waiting in the PBS line, we would be 'unique' in the world but action is unlikely before 2016, a prominent expert has said.
Aust diabetes spread mapped
Diabetes Australia has updated its map of where diabetes is concentrated in Australia, showing where the nation's one million-plus diabetics are found.
Lantus biosim launched at discount
As Lilly seeks further clarification about the PBS listing of its insulin glargine biosim, it has launched the drug in the UK at a heavy discount.
HPV vax take up is patchy
A new report should help improve Australia's immunisation rates against human papillomavirus, with coverage rates as low as 56 per cent in some areas.
Govt-backed biosim grabs market
One European government's forced switching of patients to a biosim at a massive discount has seen a quick end to the originator's market dominance.
J&J sponsors new Eureka prize
Johnson & Johnson has announced its sponsorship of a new Eureka Prize for Innovation in Medical Research.
Poisonings from pharmaceuticals fall
Poisonings by pharmaceutical substances in Australia have fallen by four per cent a year from 2005-06, making up less than two per cent of all hospitalised cases in 2012-13.
BMS's Opdivo goes back to PBAC
Despite the PBAC not releasing a result for BMS's melanoma drug
from July, the November agenda shows it has been re- submitted with a twist.
Calls for CSL to reveal Fluvax data
Researchers are calling for more transparency from CSL in relation to clinical trial data related to its
EBOS's price disclosure challenge
The EBOS Group has reported a strong FY2015 result but says PBS price disclosure is an 'ongoing challenge'.
Survey reveals recruiting challenges
Pharma in Focus' latest survey has shown that some in industry have trouble trusting recruitment firms but others are glad of their help.
FDA issues warning on Leo's Picato
Leo Pharma will have to update its label for
, its treatment for solar keratosis, after the FDA issued a safety communication.
Novo explores pharmacy partnership
Novo Nordisk is exploring the prospect of partnering with community pharmacy in diabetes management as pharmacists grow their role in primary care.
Takeda files Velcade successor
Takeda's filing of oral multiple myeloma treatment ixazomib has been accepted in Europe while Novartis has won US extension of Promacta.
Australia must agree on biosimilar approach
With the PBAC opinion on Remicade biosimilar Inflectra due today,
Dr Greg Pearce
writes it is in everyone's best interest to think beyond sectional interests and foster a sound approach to biosimilar medicine market entry.
Events & Conferences
© 2003 - 2015 Lush Media
Pharma in Focus
Jolly Good Design
christian louboutin Sandals
hermes replica belt
celine tote sale
yves saint laurent discount
prada replica bags
hermes birkin replica
hermes handbags birkin
christian louboutin pumps outlet
hermes kelly replica
chloe handbags replica
hermes replica handbags
celine trapeze sale
hermes kelly outlet
yves saint laurent shoulder bags replica
christian louboutin Sandals replica
chloe handbags online